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Abstract  69 
 70 
Background and aims: Malnutrition has been recognized as a major risk factor for adverse 71 
postoperative outcomes. The ESPEN Symposium on perioperative nutrition was held in 72 
Nottingham, UK, on 14-15 October 2018 and the aims of this document were to highlight the 73 
scientific basis for the nutritional and metabolic management of surgical patients. 74 
Methods: This paper represents the opinion of experts in this multidisciplinary field and 75 
those of a patient and caregiver, based on current evidence. It highlights the current state of 76 
the art. 77 
Results: Surgical patients may present with varying degrees of malnutrition, sarcopenia, 78 
cachexia, obesity and myosteatosis. Preoperative optimization can help improve outcomes. 79 
Perioperative fluid therapy should aim at keeping the patient in as near zero fluid and 80 
electrolyte balance as possible. Similarly, glycemic control is especially important in those 81 
patients with poorly controlled diabetes, with a stepwise increase in the risk of infectious 82 
complications and mortality per increasing HbA1c. Immobilization can induce a decline in 83 
basal energy expenditure, reduced insulin sensitivity, anabolic resistance to protein nutrition 84 
and muscle strength, all of which impair clinical outcomes. There is a role for 85 
pharmaconutrition, pre-, pro- and syn- biotics, with the evidence being stronger in those 86 
undergoing surgery for gastrointestinal cancer. 87 
Conclusions: Nutritional assessment of the surgical patient together with the appropriate 88 
interventions to restore the energy deficit, avoid weight loss, preserve the gut microbiome 89 
and improve functional performance are all necessary components of the nutritional, 90 
metabolic and functional conditioning of the surgical patient. 91 
92 
 4
1. Introduction 93 
Major surgery evokes a catabolic response that results in inflammation, protein catabolism 94 
and nitrogen losses. This response is proportional to the magnitude of the procedure and 95 
can, in some instances, be detrimental to the patient, especially when there is pre-existing 96 
malnutrition. Traditional perioperative care has involved measures that starve the patient 97 
for prolonged periods of time, stress the patient with measures that amplify this response 98 
and drown the patient with salt and water overload. However, over the past two decades, 99 
there has been a paradigm shift in perioperative care, with periods of starvation being 100 
reduced drastically, introduction of measures to reduce surgical stress and protein 101 
catabolism, and avoiding salt and water overload. The aim of modern perioperative care is to 102 
attenuate loss of or aid return to function in an accelerated manner by promoting return of 103 
gastrointestinal function, feeding the patient early, providing adequate pain relief, and 104 
encouraging early mobilization. These measures result in reduced complications, early 105 
discharge from hospital without increasing readmission rates and better functional recovery. 106 
 The European Society for Clinical Nutrition and Metabolism (ESPEN) has published 107 
updated evidence-based guidelines on perioperative nutrition recently that help aid the 108 
nutritional care of the surgical patient [1]. In further support of these guidelines, an ESPEN 109 
expert group met for a Perioperative Nutrition Symposium in Nottingham, UK on October 14 110 
and 15, 2018. The group examined the causes and consequences of preoperative 111 
malnutrition, reviewed currently available treatment approaches in the pre- and 112 
postoperative periods, and analyzed the rationale on which clinicians could take actions that 113 
facilitate optimal nutritional and metabolic care in perioperative practice. The content of this 114 
position paper is based on presentations and discussions at the Nottingham meeting along 115 
with a subsequent update of the literature. 116 
 117 
2. Historical note 118 
Our understanding of the concept of clinical nutrition and the science of human nutrition has 119 
evolved significantly over the last two decades. The role of nutrition in surgery has 120 
encompassed measures to recognize, identify and intervene in those pre-operative patients 121 
who are at risk of malnutrition with appreciable impact on post-surgical outcomes in those 122 
adequately nutritionally prehabilitated. However, it would be incorrect to consider clinical 123 
nutrition as an entirely new concept [2-4]. Ancient Egyptians were the first to be credited 124 
with descriptions befitting enteral nutritional as identified in the Ebers papyrus (c 1550 BC) 125 
[4] and feeding via the oropharyngeal and nasopharyngeal routes are from then on 126 
described throughout the antiquated medical literature. For instance, Capivacceus in the 127 
16th century, Aquapendente in the 17th century [2, 4] and the 19th century physician Dukes 128 
[5] employed these routes of nutritional delivery to treat all manner of ailments including 129 
mania, diphtheria and croup.  130 
The recognition of nutritional deficiency as a cause of illness was first presented by 131 
James Lind, a fellow of the Royal College of Physicians of Edinburgh who established the 132 
superiority of citrus fruits above all other 'remedies' in his treatise on scurvy published in 133 
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1753 [6]. The identification, characterization and synthesis of essential vitamins and minerals 134 
during the earlier part of the 20th century [7], allowing their use in the treatment of 135 
nutritional deficiency-related diseases such as scurvy, pellagra, rickets, and nutritional 136 
anemias [7].  137 
The adverse effect of weight loss on surgical outcome was documented over 80 years 138 
ago when Hiram Studley showed that, in patients undergoing surgery for perforated 139 
duodenal ulcer, postoperative mortality was 10 times greater in those who had lost more 140 
than 20% of their body weight preoperatively when compared with those who had lost less 141 
[8]. This observation generated much of the ensuing work to define the role of malnutrition, 142 
nutritional deficiencies, and perioperative nutrition in surgery. 143 
 144 
3. The malnourished surgical patient 145 
The definition of a malnourished patient is the subject of ongoing discussion. In the last 146 
decade there have been considerable efforts to rationalize various definitions generally, and 147 
in the cancer patient for whom surgery is commonly the primary modality for cure. The 148 
starting point for much of this work was the international consensus of 2011 [9]. In this 149 
publication, cancer cachexia was defined as “a multifactorial syndrome defined by an 150 
ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully 151 
reversed by conventional nutritional support and leads to progressive functional 152 
impairment.” There was a recognition of the role of the systemic inflammatory response in 153 
the symptoms associated with cachexia. Serum CRP was agreed to be an important 154 
biomarker, but it was recognized that cachexia can be present in the absence of overt 155 
systemic inflammation [10]. 156 
In the intervening years with greater knowledge of the importance of systemic 157 
inflammatory responses in the progressive nutritional and functional decline of patients with 158 
cancer, this statement has been increasingly called into question and measurement of the 159 
magnitude of the systemic inflammatory is now integral to the definition and treatment of 160 
cancer cachexia [11-14]. This more nuanced definition reflects the evolution of criteria in the 161 
definition of malnutrition in which cancer cachexia is considered as part of disease related 162 
malnutrition with inflammation [15, 16]. For example, approximately 40% of patients with 163 
operable colorectal cancer considered at medium or high nutritional risk (malnutrition 164 
universal screening tool – MUST [17]) had evidence of systemic inflammation (CRP>10 mg/L) 165 
[18]. 166 
 167 
4. Sarcopenia, sarcopenic obesity and myosteatosis 168 
Patients may present to surgery with a range of underlying nutritional syndromes and 169 
phenotypes, such as malnutrition, sarcopenia, cachexia, obesity and myosteatosis. 170 
Furthermore, these phenotypes are associated with worsened post-operative outcome. 171 
However, screening for such syndromes is not necessarily performed routinely in clinical 172 
practice, and there is no one screening tool that is capable of distinguishing one syndrome 173 
from another [19].  174 
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4.1 Sarcopenia 175 
A recent study showed that the surgical population in the UK tends to be older than the 176 
general population, and that the age gap is increasing with time. Between 1999 and 2015, 177 
the percentage of people aged 75 years or more undergoing surgery increased from 14.9% 178 
to 22·9%, and this figure is expected to increase further [20]. Sarcopenia is described as ‘the 179 
loss of skeletal muscle mass and strength as a result of ageing’. There are a number of 180 
definitions for sarcopenia, which rely on the measurement of the combination of both 181 
muscle function and muscle mass. These include the European Working Group of Sarcopenia 182 
in Older Persons (EWGSOP) [21], the International Working Group on Sarcopenia (IWGS) 183 
Sarcopenia Task Force [22], the Asian Working Group for Sarcopenia and the Foundation for 184 
the National Institutes for Health (Table 1) [10, 21-25].  185 
More recently, the term “sarcopenia” has taken on a different usage. The use of 186 
diagnostic cross-sectional computed tomography (CT) images at the third lumbar vertebral 187 
level (L3) for the simultaneous perioperative analysis of body composition has become 188 
increasingly popular [26]. In this surgical context, sarcopenia has come to mean reduced 189 
muscularity, without assessment of patient functional status. Rather than assessing skeletal 190 
muscle mass, this CT technique analyses cross-sectional skeletal muscle area which is then 191 
indexed to patient height to give a skeletal muscle volume. This technique also provides data 192 
on the mean skeletal muscle radiodensity, quoted in Hounsfield Units (HU), which is a 193 
surrogate marker of muscle quality and an indication of the presence of myosteatosis, as 194 
well as adiposity in terms of both visceral and subcutaneous fat cross-sectional area and 195 
indices. There is a large volume of literature linking preoperative sarcopenia in a range of 196 
different pathologies, including pancreatic surgery [27], gastric cancer surgery [28], 197 
esophageal cancer [29], liver transplantation [30] and colorectal cancer [31] to worsened 198 
clinical outcomes and overall survival. The strength of this relationship is even greater when 199 
the presence of sarcopenia is combined with obesity, i.e. low muscle volume in association 200 
with elevated body adiposity. A recent meta-analysis has examined this relationship in 2297 201 
patients with pancreatic ductal adenocarcinoma, finding both sarcopenia and sarcopenic 202 
obesity to be associated with poorer overall survival (HR 1.49, p<0.001 and HR 2.01, 203 
p<0.001) [32].  204 
However, there are problems of interpretation in the literature, often due to 205 
heterogeneity in the methodology of the studies leading to variability in results. There has 206 
been a degree of variability in the cut-offs used for the diagnosis of sarcopenia (and 207 
myosteatosis). However, there are well validated BMI and gender-specific cut-offs available 208 
in the literature for cancer patients [33]. The validated technique uses CT-based analysis at 209 
the L3 level, as this was the level that the initial validation calculations were performed in 210 
order to extrapolate to the whole body. Recently, several studies have looked at body 211 
composition analysis at the fourth thoracic vertebra as an alternative in patients who are 212 




4.2 Myosteatosis 216 
Myosteatosis is the infiltration of skeletal muscle by fat, into both intermuscular and 217 
intramuscular compartments. There are a multitude of different terms used synonymously 218 
with myosteatosis, including muscle quality, radiodensity, and muscle attenuation. There has 219 
been significant research interest in the impact of myosteatosis on surgical outcomes in a 220 
range of different cancer types, including periampullary [35], ovarian [36] and rectal cancer 221 
[37]. As with the relationship between sarcopenia and obesity, there also appears to be a 222 
combined effect with myosteatosis and obesity. In a series of 2100 patients undergoing 223 
elective colorectal cancer surgery, three body composition subtypes were independent 224 
predictors of hospital length of stay; combined sarcopenia and myosteatosis (incidence rate 225 
ratio (IRR) 1.25,), visceral obesity (IRR 1.25,) and myosteatosis combined with sarcopenia 226 
and visceral obesity (IRR 1.58). The risk of readmission was associated with visceral obesity 227 
alone (OR 2.66, p=0.018), visceral obesity combined with myosteatosis (OR 2.72, p=0.005) 228 
and visceral obesity combined with both myosteatosis and sarcopenia (OR 2.98, p=0.038). 229 
There is also emerging evidence that low skeletal muscle radiodensity is involved in the 230 
etiology of, or shares mechanisms with, other comorbidities such as myocardial infarction, 231 
diabetes and renal failure [38].  232 
 233 
4.3 Cachexia 234 
The third body composition syndrome of interest is cachexia, which occurs as a consequence 235 
of a range of diseases, including cancer, chronic obstructive pulmonary disease, cardiac 236 
failure, renal failure and rheumatoid arthritis. Cachexia is multifactorial in etiology [39]. For 237 
example, in patients with cancer, not only is the tumor a potential driver for nutritional 238 
depletion, but patients also tend to be older (hence, sarcopenic), live a sedentary lifestyle, 239 
and often have a poor diet, as well as have other comorbidities which may impact upon 240 
body composition. Recent evidence also suggests that some cancer patients may have a 241 
genetic predisposition to weight loss and low muscularity [40]. 242 
There have been a number of definitions of cachexia published previously [25, 41-243 
43]. However, the most accepted definition of cancer cachexia is ‘’a multifactorial syndrome 244 
defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that 245 
cannot be fully reversed by conventional nutritional support and leads to progressive 246 
functional impairment’ [10]. This international consensus provided diagnostic criterial which 247 
were either weight loss exceeding 5% or weight loss greater than 2% in individuals already 248 
showing depletion as marked by a BMI <20 kg/m2 or the presence of sarcopenia.  249 
The interaction and overlap between sarcopenia, myosteatosis and cancer cachexia 250 
are not currently well understood. In addition, the interaction between these skeletal 251 
muscle variants and patient adiposity and frailty are not clear and these should be the focus 252 




5. The metabolic response to immobilization and surgical trauma 256 
There are a number of different factors which contribute to the peri- and post-surgical 257 
trauma phenotype including immobilization, reduced oral intake, anesthesia, tissue damage, 258 
subsequent immune system activation and metabolic changes.  259 
There are significant metabolic changes associated with a period of bedrest which 260 
are paralleled in the metabolic changes occurring after surgery [44] as immobilization is one 261 
of the key components of postoperative changes. These negative changes are also observed 262 
in clinical populations and sarcopenic or frail older adults [45] and include a decline in basal 263 
energy expenditure, reduced insulin sensitivity, anabolic resistance to protein nutrition, 264 
muscle strength and physical performance as well as increased risk of falls, health-related 265 
expenditure, morbidity and mortality. The larger impact of bed rest on the rate of loss of 266 
lean muscle leg mass and strength during bedrest in healthy older adults than their young 267 
counterparts is equivocal [46, 47]. On the other hand, gain of muscle mass and function as a 268 
consequence of exercise requires significant regular training over an extended period of 269 
time, with evidence suggesting that 12 weeks of resistance exercise training is necessary for 270 
a 1.5 kg gain in muscle mass in older adults [45].  271 
As the process of muscle loss requires a considerably shorter period of time in older 272 
adults, with just seven days of bedrest resulting in 1 kg loss of lean leg muscle mass, there 273 
should, therefore, be a particular emphasis on the preservation of muscle mass during 274 
periods of muscle disuse whilst older patients are in hospital. This loss of muscle mass occurs 275 
in both the type I (slow twitch) and type II (fast twitch) skeletal muscle fibers [48]. In terms 276 
of muscle strength, the initial loss of strength occurs rapidly during a period of 277 
immobilization, irrespective of the cause of immobilization. However, this loss of strength 278 
then plateaus after around 30 days. 279 
 Older adults tend to stay longer in hospitals and after discharge experience a more 280 
pronounced decrease in ambulatory function and reduced ability to complete activities of 281 
daily living. There are a number of strategies which have been recommended to reduce 282 
muscle wasting during bedrest in older adults, including resistance exercise [49], dietary 283 
interventions such as an increase in protein intake to exceed 1 g/kg body weight/day, 284 
administration of essential amino acid (EAA) mixtures [50, 51], as well as the combination of 285 
these EAA mixtures with carbohydrate [52] or leucine, valine and isoleucine. A study [51] on 286 
the role of essential amino acids in older adults undergoing 10 days best rest found that 287 
although this normalized muscle protein synthesis, it did not have an effect upon skeletal 288 
muscle loss or function. However, when beta-hydroxy-beta-methylbutyrate (HMB) 289 
supplementation was used in a randomized placebo-controlled trial [46] in healthy 290 
volunteers undergoing a period of 10 days bedrest, this resulted in a significant reduction in 291 
the amount of muscle loss associated with the bedrest as well as an increase in muscle mass 292 
gain during the 8 week rehabilitation phase, both in terms of total lean mass and total leg 293 
lean mass. Muscle strength also appeared to be preserved in this study.  294 
There are many parallels to that associated with immobilization when bedrest as a 295 
consequence of surgery is considered. Preoperative fasting is associated with characteristic 296 
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metabolic changes. After just a short overnight fast, the body remains able to cope with the 297 
glucose demands placed on it by the muscle, brain, kidney, bone marrow and lymph nodes 298 
by the breakdown or glycogen within the liver. However, after starvation of 24 hours, the 299 
metabolic response changes to the breakdown of adipose tissue to mobilize fatty acids 300 
which are utilized by the muscle and kidney. When more prolonged periods of fasting are 301 
considered, the metabolic response become somewhat more complex. Muscle protein 302 
breakdown releases amino acids such as alanine and glutamine which are used in the kidney 303 
and liver to promote gluconeogenesis, with persistence of adipose tissue breakdown to 304 
provide ongoing energy stores.  305 
Resting energy expenditure (REE) increases after surgery, with the degree 306 
determined by the magnitude of the insult, with most pronounced changes observed in 307 
those following major burns, followed by those with sepsis or peritonitis. Elective surgery is 308 
associated with a much lower increase in REE. The metabolic response to surgical trauma 309 
allows mobilization of glucose and glutamine to provide substrate for wound healing, and 310 
amino acids for acute phase protein synthesis. Intensive care unit stay is also associated with 311 
a typical pattern of skeletal muscle loss [53] which is far more rapid than that seen after a 312 
standard surgical insult.  313 
Surgery results in an overall reduction in lean leg muscle mass [54]. However, when 314 
protein turnover is examined, there is not a large difference between the pre- and post-315 
operative phases. When patients are fed postoperatively, this results in a significant increase 316 
in protein synthesis rates and reduction in protein breakdown when compared with patients 317 
who were fasted postoperatively [54]. Changes in skeletal muscle mass and function 318 
following surgery are most likely the consequence of inactivity combined with reduced food 319 
intake and specific metabolic changes. 320 
 321 
6. Nutrition and surgical outcome – lessons from the ESPEN nutritionDay  322 
In the nutritionDay dataset [55] (155 524 patients) 41% of the enrolled participants were 323 
surgical patients. The median length of stay for the cross-sectional nutritionDay data 324 
collection was 6 days for surgical and non-surgical patients [56]. Surgical patients were 6 325 
years younger than non-surgical patients (63 vs. 69 years, p<0.001). BMI was similar in 326 
surgical and non-surgical patients. BMI was <18.5 kg/m2 in 7.1% of patients and was >30 327 
kg/m2 in 19%.  328 
Weight loss within the last 3 months was slightly less frequent in surgical patients 329 
(39%) than in non-surgical patients (43%) (p<0.0001) while stable weight was more frequent 330 
in surgical patients (40% vs. 33%, p<0.0001). Reduced intake in the week before 331 
nutritionDay” was slightly less frequent in surgical (44%) than in non-surgical (46%) patients 332 
(p<0.0001). On nutritionDay the full served meal was eaten by only 35% of surgical patients 333 
vs 38% of non-surgical patients. Nothing was eaten by 20% of surgical patients and 11% of 334 
non-surgical patients mostly because they were not allowed to eat. The high proportion of 335 
surgical patients with nothing eaten on nutritionDay is shown in Figure 1 for preoperative, 336 
postoperative and non-surgical patients. Artificial nutrition was used in a minority of patients 337 
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eating nothing. In patients not allowed to eat 30% received artificial nutrition, and in 338 
patients eating nothing despite being allowed to eat 27% received artificial nutrition. 339 
Reduced eating was associated with a delay in discharge of about 1 day. Outcome at day 30 340 
after nutritionDay was available for 83% of patients. Most patients (72.5%) were discharged 341 
home 3.8% had died in hospital. Mortality was lower in surgical patients (2%) when 342 
compared with non-surgical patients (5%).  343 
Weight loss was associated with a slightly higher odds ratio for death in hospital 344 
within 30 days in surgical patients when compared with non-surgical patients (OR 3.2 vs 2.5). 345 
Reduced intake in the previous week was associated with a progressive increase in death 346 
within 30 days from OR 2.0 for less than normal eating, OR 3.6 for eating half and OR 6.4 for 347 
eating less than a quarter. This association was similar at all levels to non-surgical patients. 348 
Eating half the recommended amount in hospital on nutritionDay was associated with an OR 349 
2.3 of death whereas eating nothing despite being allowed to eat was associated with an OR 350 
9.0 (Figure 1). 351 
 352 
7. The patient at risk and nutritional assessment 353 
The German hospital malnutrition study [57] found that overall 27.4% of patients were 354 
diagnosed with malnutrition according to the subjective global assessment (SGA), with a 355 
huge degree of variability between specialties. In patients who had undergone major 356 
abdominal surgery the prevalence of malnutrition was 44%, with lowest rates in those 357 
undergoing chest or general surgery (20% and 14%, respectively). A study of 26 hospital 358 
departments spread across the European Union using the nutritional risk screening (NRS-359 
2002) tool identified that 32.6% of patients were at ‘high risk’ of malnutrition, with these 360 
patients developing more complications (30.6% vs 11.3% p<0.001) , increased mortality rates 361 
(12% vs. 1%, p<0.001) and longer hospital length of stay (median 9 vs. 6 days, p<0.001) when 362 
compared with patients who were ‘not-at-risk’. A progressive degree of malnutrition, from 363 
none to severe, has been associated with progressive increased risk of morbidity and 364 
mortality as well as increased ICU admission and overall hospital length of stay in patients 365 
undergoing liver transplantation [58]. This relationship of increased morbidity and mortality 366 
amongst those with malnutrition is also seen in those undergoing abdominal surgery for 367 
cancer [59].  368 
Many of the screening tools used historically to identify those at high risk of 369 
malnutrition considered only single parameters. However, these do not facilitate the 370 
identification of patients’ preoperative nutritional status, nor do they precisely identify those 371 
at high nutritional risk [60]. A validated screening tool offers a far superior method for 372 
identifying those at high risk of malnutrition correctly. Four central criteria were proposed to 373 
identify those at high nutritional risk; body mass index (BMI) and a detailed nutritional 374 
history, the presence of pathological weight loss, appetite and food intake and the severity 375 
of the underlying disease. This led to the development of a range of screening tools including 376 
the malnutrition screening tool (MST), the malnutrition universal screening tool (MUST) [17], 377 
the nutrition risk index (NRI) [61], the subjective global assessment (SGA) [62], the mini 378 
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nutritional assessment short form (MNA-SF) [63] and the nutritional risk screening (NRS-379 
2002) [64]. There is only expert consensus regarding the best screening tool available for 380 
nutritional risk assessment, which suggests that the MUST is superior in the community, NRS 381 
2002 for inpatients and SF-MNA for those in older adult care homes. A multitude of studies 382 
have subsequently been performed to validate the predictive value for complications and 383 
mortality of preoperative NRS 2002 in patients undergoing surgery, including gastric cancer 384 
surgery [65], colorectal surgery [66] and major gastrointestinal surgery [67, 68]. A meta-385 
analysis [69] examining the use of NRS 2002 as a predictor of postoperative outcomes in 386 
abdominal surgery included a total of 11 studies. Postoperative complications were more 387 
frequent in those deemed ‘at risk’ than those ‘not-at-risk’ (OR 3.13, p<0.00001). Mortality 388 
was also higher in patients ‘at risk’ (OR 3.61, p=0.009) and these patients had a significantly 389 
longer hospital LOS (mean difference 3.99 days, p=0.01) [69].  390 
More recent guidelines [1] have explored criteria for the diagnosis of severe 391 
nutritional risk, and these have included weight loss exceeding 10-15% within the preceding 392 
6 months, BMI less than 18.5 kg/m2, NRS 2002 >5 or SGA grade C or a preoperative serum 393 
albumin concentration less than 30 g/L in the absence of hepatic or renal dysfunction. If one 394 
of these criteria is present, targeted nutritional therapy should be instigated immediately. If 395 
the screening tools discussed previously identify a patient at risk, a more formal and 396 
extensive nutritional assessment should be performed by an appropriately trained 397 
professional. This assessment should include nutritional assessment using a plate chart or 398 
24-hour dietary recall, estimation of patients subcutaneous and visceral adiposity and 399 
skeletal muscle mass, other anthropometrics measures such as upper arm circumference 400 
and skin-fold thickness; hand-grip strength as a test of muscle function; and Barthel index or 401 
6-minute walking test as a measure of body function [70].  402 
 403 
8. Preoperative nutritional and metabolic preparation of the surgical patient 404 
Preoperative conditioning is defined as the process of training to become physically fit by a 405 
regimen of exercise, diet and rest and is, therefore, regarded as a multimodal intervention. 406 
Perioperative oral nutrition is considered one of the major preoperative components of 407 
Enhanced Recovery After Surgery (ERAS) pathways [71]. ERAS is believed to help by 408 
‘exploiting the critical perioperative period to improve long-term cancer outcomes’ [72], and 409 
optimization of nutrition is one area which can be exploited successfully.  410 
The concept of preoperative conditioning is not a new one. In 1992 the concept of a 411 
‘decision box’ [73] which helps to identify the right patients who will benefit most from a 412 
nutritional intervention, was devised. Given the high prevalence of malnutrition discussed in 413 
the previous section and the known risk factors, which are highly prevalent amongst those 414 
undergoing surgery, this should be aggressively targeted. The metabolic risk is exacerbated 415 
in patients with malignancy [74] due to release of TNF-alpha, IL-6 and IL-1 in addition to 416 
anorexia caused by central nervous system signaling which results in muscle wasting, 417 
changes in liver metabolism as well as consumption and depletion of fat stores. Exercise is 418 
one modality which can help modulate these metabolic consequences of tumor, by 419 
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promoting IGF-1, mTOR, and Akt which results in increased protein synthesis; IL-10, sTNF-r1 420 
and sTNF-r2 which reduces systemic inflammation; GLUT-4 which reduces insulin resistance 421 
and SOD and GSH which results in a reduction in the formation of reactive oxygen species 422 
[75]. 423 
The aims of preoperative conditioning are to restore the energy deficit, improve 424 
functional performance, avoid weight loss and preserve the gut microbiome. To obtain such 425 
effect, a normocaloric diet is sufficient with a protein intake of 1.2 g/kg [76]. The 426 
intervention should include dietary counselling, fortified diets, oral nutritional 427 
supplementation (ONS), and parenteral support, where indicated. The enteral route is 428 
always preferred wherever feasible and even when patients are consuming a normal diet 429 
this is frequently insufficient to obtain their energy requirement, so it is recommended that 430 
patients receive oral nutritional supplements (ONS) in the preoperative period, irrespective 431 
of their nutritional status [1]. There is good evidence to support ONS in the perioperative 432 
period, with a meta-analysis of 9 studies [77] finding this to be associated with a 35% 433 
reduction in total complications (p<0.001) and this translated to a cost saving and to be cost 434 
effective. In those patients who are identified as high-risk undergoing major abdominal 435 
surgery and those who are malnourished with a diagnosis of cancer, ONS should be 436 
considered obligatory [1]. In terms of parenteral nutrition (PN), this should only be 437 
considered in those with malnutrition or severe nutritional risk where emergency 438 
requirements cannot be met by enteral nutrition interventions alone [1]. Where this 439 
approach is absolutely necessary, PN should be provided for 7-14 days preoperatively to 440 
maximize benefit, based upon evidence that this time frame is necessary to reduce the 441 
Clavien-Dindo grade 3b or higher surgical site infection-based complications [78].  442 
The use of carbohydrate loading as metabolic conditioning is supported by some 443 
basic science and clinical studies [79, 80]. A recent large prospective randomized clinical trial 444 
has shown significant benefits regarding the reduction of postoperative insulin resistance 445 
and hyperglycemia without impact on the complication rate [81]. So far, the evidence for a 446 
decrease of postoperative morbidity is not yet clear. 447 
Prehabilitation has gained popularity in recent times, with increasing evidence to 448 
support a multimodal prehabilitation program in a range of surgical specialties. A study 449 
combining a 6-week preoperative bundle of physical exercise and endurance training, 450 
nutrition interventions and psychological support to improve anxiety when compared to 451 
postoperative rehabilitation alone [82] in a cohort of patients undergoing elective colorectal 452 
surgery found that this optimizes the patients functional capacity throughout the 453 
perioperative period. In those patients who are due to undergo preoperative neoadjuvant 454 
therapy, the period after cessation of therapy but prior to surgery is typically 4 to 6 weeks 455 
and this time should be exploited to optimize patient fitness. A meta-analysis of multimodal 456 
prehabilitation [83] in elective colorectal surgery found that this was associated with a 457 
significant reduction in hospital LOS of 2 days and was linked to a faster time to return to 458 
presurgical functional capacity. When pooled data from RCTs regarding trimodal 459 
prehabilitation was analyzed [84], this found that the postoperative loss of lean body mass 460 
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was attenuated in patients undergoing prehabilitation versus rehabilitation alone. There is 461 
also support that a multimodal intervention is associated with improved perioperative 462 
physiological parameters, functional outcomes and quality of life measures, but no impact 463 
on postoperative complications in those undergoing liver resection [85] as well as a 464 
beneficial effect in muscle strength in sarcopenic older adult patients undergoing gastric 465 
cancer resection [86]. In high-risk patients undergoing elective major abdominal surgery, a 466 
randomized controlled trial found that prehabilitation in the form of a motivational 467 
interview, high-intensity endurance training and promotion of physical activity was 468 
associated with a significant reduction in the incidence of postoperative complication [87] 469 
(31% vs. 62%, p=0.001). 470 
 471 
9. Perioperative glycemic control 472 
Hospital guidelines surrounding perioperative glycemic control are based, in 90% of cases, 473 
on the guidance published by Diabetes UK in 2011 [88]. This provides a standard of care, 474 
which should be met commencing at the point of referral from primary care, through the 475 
perioperative stage and to discharge from hospital. At the first stage when the patient is 476 
referred from primary care, the minimum information that should be provided should 477 
include the duration and type of diabetes, the place of usual diabetes care (primary or 478 
secondary), other comorbidities, and treatment (both for the diabetes and other 479 
comorbidities). Information should also be provided on details of any diabetes-associated 480 
complications such as renal or cardiac disease, and finally any relevant measures from within 481 
the last 3 months, including body mass index (BMI), blood pressure, HbA1c and eGFR. 482 
However, the compliance to this standard was low [89]. 483 
There is evidence supporting an association between the presence of diabetes and 484 
significantly elevated risk of 30-day mortality in patients undergoing elective non-cardiac 485 
surgery [90]. Those patients with diabetes (20.2%) with preoperative hyperglycemia (7.9%) 486 
were twice as likely to die as those with a normal preoperative glucose concentration. 487 
However, if the patient did not have preoperatively diagnosed diabetes but had 488 
preoperative hyperglycemia, they were 13 times more likely to die within 30 days of surgery 489 
when compared with a patient with normal preoperative glucose concentration. When 490 
postoperative hyperglycemia was considered, if the patient were not diagnosed with 491 
diabetes but had perioperative or postoperative hyperglycemia, they were 45 times more 492 
likely to die than those with normal glucose concentration. There is also an association 493 
between hyperglycemia in those who were previously normoglycemic and composite 494 
adverse events [91], as well as reoperative interventions, anastomotic failures, myocardial 495 
infarction and composite infections [92]. However, knowing that the patient was diabetic in 496 
the presence of hyperglycemia attenuated these worse clinical outcomes by almost half. 497 
There is consistent evidence that the highest risk group with regards to perioperative 498 
glucose control are those who are not diagnosed with diabetes but who develop 499 
postoperative hyperglycemia.  500 
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Clinical outcomes in those with poorly controlled diabetes are significantly worse 501 
than those with well-controlled diabetes, with a stepwise increase in the risk of infectious 502 
complications and mortality relating to infection according to increasing HbA1c (RR 0.98, if 503 
HbA1c <6% versus RR 2.01, if HbA1c ≥11%) [93]. Patients with highest preoperative HbA1c 504 
levels tend to have their blood glucose levels checked earlier, have higher postoperative 505 
glucose concentrations and are significantly more likely to be commenced on insulin 506 
postoperatively, than those with a lower preoperative HbA1c, possibly due to an elevated 507 
level of vigilance [94].  508 
The current National Institute for Health and Care Excellence (NICE) clinical guideline 509 
45 surrounding the use of routine preoperative tests prior to elective surgery suggests that 510 
HbA1c should only be routinely tested in those patients with a formal diagnosis of diabetes 511 
[95]. However, this is a controversial policy as it fails to identify those patients with non-512 
diabetic hyperglycemia [96] and, therefore, misses the opportunity to intervene 513 
preoperatively and modify the elevated perioperative surgical risk that this is associated 514 
with.  515 
 516 
10 Perioperative fluids and outcome 517 
There is a close relationship between nutrition and fluid and electrolyte balance, with the 518 
intake of food by natural or artificial means being inseparable from that of fluid and 519 
electrolytes [97]. The metabolic response to surgery is associated with salt and water 520 
retention and an increase in the excretion of potassium, as a result of which patients are 521 
susceptible to retention of salt and water, and consequent fluid overload in the 522 
perioperative period [98-103]. There is a relatively narrow margin of safety in perioperative 523 
fluid therapy and either too much or too little can have a negative effect on physiological 524 
processes and clinical outcome. The goal of perioperative intravenous fluid therapy should 525 
be to maintain tissue perfusion and cellular oxygen delivery, while at the same time keeping 526 
the patient in as near zero fluid and electrolyte balance as possible (Figure 2). 527 
 528 
10.1 Preoperative period 529 
Patients should reach the anesthesia room in a state as close to euvolemia as possible with 530 
any preoperative fluid and electrolyte imbalance having been corrected. Current anaesthetic 531 
recommendations that allow patients to eat for up to 6 h and drink clear fluids up to 2 h 532 
prior to the induction of anesthesia help to prevent preoperative fluid depletion without 533 
increasing aspiration-related complications. Some patients may need intravenous fluids to 534 
restore euvolemia prior to surgery. 535 
 536 
10.2 Intraoperative period  537 
Most patients require crystalloids at a rate of 1-4 ml/kg/h to maintain homeostasis [104]. 538 
However, some patients develop intravascular volume deficits which require correction by 539 
administration of goal-directed boluses of intravenous solutions. Goal directed fluid therapy 540 
(GDFT) is aimed at maintaining intravascular normovolemia guided by changes in stroke 541 
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volume as measured by a minimally invasive cardiac output monitor to optimize the position 542 
of each patient on his/her individual Frank–Starling curve [105, 106]. In addition to the 543 
background crystalloid infusion, fluid boluses (200-250 ml) should be given to treat any 544 
objective evidence of hypovolaemia (>10% fall in stroke volume) in order to optimise 545 
intravascular volume and cardiac output [107]. A recent meta-analysis that included 23 546 
studies with 2099 patients has shown that GDFT was associated with a significant reduction 547 
in morbidity, hospital length of stay, intensive care length of stay, and time to passage of 548 
feces [108]. However, when patients were managed within ERAS pathways, with optimal 549 
perioperative care and avoidance of postoperative fluid overload, the only significant 550 
reductions were in length of intensive care stay and time to passage of feces. It has also been 551 
shown that GDFT does not impact on outcome when compared with conventional 552 
intraoperative fluid therapy in patients undergoing elective colorectal surgery [109]. Hence, 553 
within ERAS programmes, it may not be necessary to offer all patients GDFT, which should 554 
be reserved for high risk patients or for patients undergoing high risk procedures [104].  555 
 556 
10.3 Postoperative period  557 
For most patients undergoing elective surgery, intravenous fluid therapy is usually 558 
unnecessary beyond the day of operation, except for those undergoing upper 559 
gastrointestinal and pancreatic procedures. With these exceptions, patients should be 560 
encouraged to drink as soon as they are awake and free of nausea after the operation. An 561 
oral diet can usually be started on the morning after surgery [110, 111]. When adequate oral 562 
fluid intake is tolerated, intravenous fluid administration should be discontinued and be 563 
restarted only if required to maintain fluid and electrolyte balance. If intravenous fluids are 564 
required, then in the absence of ongoing losses, only maintenance fluids should be given at a 565 
rate of 25-30 ml/kg/day with no more than 70-100 mmol sodium/day, along with potassium 566 
supplements (up to 1 mmol/kg/day) [112]. As long as this volume is not exceeded, 567 
hyponatraemia is very unlikely to occur despite the provision of hypotonic solutions [113, 568 
114]. Any ongoing losses (e.g. vomiting or high stoma losses) should be replaced on a like-569 
for-like basis, in addition to maintenance requirements. After ensuring the patient is 570 
normovolemic, hypotensive patients receiving epidural analgesia should be treated with 571 
vasopressors rather than indiscriminate fluid boluses [115, 116]. Fluid deficit or overload of 572 
as little as 2.5 L [117] can cause adverse effects in the form of increased postoperative 573 
complications, prolonged hospital stay and higher costs due to increased utilisation of 574 
resources [118-120].  575 
An excess of 0.9% saline causes hyperosmolar states, hyperchloremic acidosis [121-576 
126], and decreased renal blood flow and glomerular filtration rate, which in turn 577 
exacerbates sodium retention. Edema impairs pulmonary gas exchange and tissue 578 
oxygenation leading to an increase in tissue pressure in organs such as the kidney which are 579 
surrounded by a non-expansible capsule. Microvascular perfusion is compromised, arterio-580 
venous shunting increases and lymphatic drainage is reduced, leading to further edema. 581 
Hyperchloremic acidosis, as a result of saline infusions has been shown to reduce gastric 582 
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blood flow and decrease gastric intramucosal pH in older adult surgical patients, and both 583 
respiratory and metabolic acidosis have been associated with impaired gastric motility. Fluid 584 
overload also causes splanchnic oedema resulting in increased abdominal pressure, ascites 585 
and even the abdominal compartment syndrome, which may lead to decreased mesenteric 586 
blood flow and ileus, with delayed recovery of gastrointestinal function, an increase in gut 587 
permeability, intestinal failure and even anastomotic dehiscence [127].  588 
Fluid restriction resulting in fluid deficit can be as detrimental as fluid excess by 589 
causing decreased venous return and cardiac output, diminished tissue perfusion and 590 
oxygen delivery and increased blood viscosity. It can also lead to an increase in the viscosity 591 
of pulmonary mucus and result in mucous plug formation and atelectasis [128]. Induction of 592 
anaesthesia in patients with a fluid deficit further reduces the effective circulatory volume 593 
by decreasing sympathetic tone. Inadequate fluid resuscitation and decreased tissue 594 
perfusion can lead to gastrointestinal mucosal acidosis and poorer outcome.  595 
 A meta-analysis of patients undergoing major abdominal surgery has shown that 596 
patients managed in a state of near-zero fluid and electrolyte balance had a 59% reduction 597 
in risk of developing complications when compared with patients managed in a state of fluid 598 
imbalance (deficit or excess). There was also a 3.4-day reduction in hospital stay in the near-599 
zero fluid balance group [120].  600 
 601 
11. Inflammation and surgical outcome  602 
The “trauma of surgery” leads to release of stress hormones and inflammatory mediators. 603 
This so-called metabolic stress is akin to the “Systemic Inflammatory Response Syndrome” 604 
(SIRS) that follows any injury or infection and is mediated by cytokines.  This syndrome 605 
induces catabolism of stores of glycogen, fat and protein leading to release of glucose, free 606 
fatty acids and amino acids into the circulation – to support the process of tissue healing. It 607 
is therefore important to have sufficient protein reserves, preoperatively. This is because 608 
current thinking is that, whilst postoperative nutritional therapy may provide the energy for 609 
optimal healing and recovery, in the immediate postoperative phase it may only minimally 610 
counteract muscle catabolism, or not at all [1]. The consequences of insufficient protein 611 
reserves in the postoperative patient includes: decreased wound healing, decreased immune 612 
response, defective gut-mucosal barrier and decreased mobility and respiratory effort. All of 613 
these would lead to an overall poorer postoperative course [129].  614 
11.1 Systemic inflammatory response (SIR) 615 
As described in the American critical care medicine consensus [130], SIRS is described by any 616 
two of the following: a temperature >38°C (100.4°) or <36°C (96.8°F); heart rate >90 617 
beats/min; respiratory rate >20 breaths/min or PaCO2 <32 mmHg; white blood cells > 12 × 618 
109 cells/l or < 4 × 109 cells/l or >10% immature (band) forms [130] as well as the absence of 619 
a source of an infective focus [130]. In addition to this definition there many 620 
pathophysiological changes that occur as part of the systemic inflammatory response (Table 621 
2) [131]. 622 
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11.2 The importance of C-reactive protein (CRP) 623 
The prototypical marker of the systemic inflammatory response is CRP. A systematic review 624 
that explored routine clinical markers and their association to the magnitude of systemic 625 
inflammatory response after surgery – found that even though cortisol, IL-6, WCC, and CRP 626 
all peak after all types of elective operations (minor and major, laparoscopic and open), only 627 
IL-6 and CRP were consistently associated with the magnitude of the operative injury [132]. 628 
CRP is routinely measured in clinical laboratories world-wide and used extensively in clinical 629 
practice and therefore may be useful in the monitoring and modulation of the SIR after 630 
elective operation. A systematic review and meta-analysis that included 22 studies, of which 631 
16 studies were eligible for meta-analysis, found that the pooled negative predictive value 632 
(NPV) of CRP improved each day after surgery up to 90% at postoperative day (POD) 3 for a 633 
pooled CRP cutoff of 159 mg/L [133], and concluded that infectious complications after 634 
major abdominal surgery are very unlikely in patients with a CRP below 159 mg/L on POD 3 635 
[134]. Another systematic review and pooled-analysis evaluating the predictive value of CRP 636 
for major complications after major abdominal surgery calculated a prediction model based 637 
on major complications as a function of CRP levels on the third postoperative day [135]. 638 
Based on the model a two cut-off system was suggested consisting of a safe discharge 639 
criterion with CRP levels below 75 mg/L and above 215 mg/L serving as a predictor of 640 
complications [135]. 641 
This work highlights the clinical utility of CRP to identify the magnitude of the effect 642 
of surgery on post-operative protein catabolism and clinical outcomes. Also, CRP provides an 643 
indicator on which to judge the effect of interventions to mitigate the effects of the SIR in 644 
the post-operative period. In this context there is good evidence to support the use of 645 
laparoscopic surgery [136] and pre-operative steroids [137]. Also, there is some evidence 646 
that supports the use of pre-operative oral antibiotics in combination with mechanical bowel 647 
preparation [138, 139]. 648 
The importance of systemic inflammation and its effects on the surgical patient are 649 
summarized in Table 3. 650 
 651 
12. The impact of enhanced recovery after surgery 652 
Enhanced Recovery After Surgery (ERAS) is a relatively new pathway of care for the surgical 653 
patient [140]. It is a multi-modal, multi-disciplinary and evidence-based approach to the 654 
care, where teams of professionals work together to achieve best practice at all times, but 655 
also to be ready and able to adapt and adopt new improvements.  656 
The first evidence-based guidance for the entire perioperative care of a patient 657 
undergoing major surgery was published in 2005 [71]. The literature showed clear evidence 658 
of benefit for avoiding bowel preparation, wound drains, nasogastric tubes, removing 659 
urinary catheters, stopping intravenous fluids early and allowing early feeding. Modern 660 
fasting guidelines allowing drinking of clear fluids two hours before surgery, and avoiding 661 
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long acting premedication. Long-acting anesthetic agents and opioids for pain management 662 
should be adopted (Figure 3). All these treatments had good evidence for their use but were 663 
rarely practiced at that time. The evidence is constantly being updated and 664 
recommendations may change as the evidence base increases. This is exemplified by that 665 
fact that although mechanical bowel preparation on its own is of no benefit [141], the 666 
combination of oral antibiotics and mechanical bowel preparation may reduce surgical site 667 
infections and anastomotic leaks [139]. 668 
However, it was found that a protocol on its own was not enough. The care around 669 
the patients and the hospital management infrastructure needed to be organized differently 670 
[142]. First of all, there is a need to audit what is actually being done with regard to all the 671 
recommended ERAS care elements. The patient is passing through several units and 672 
different departments during the care process. In each one of these, many professionals are 673 
managing their specific focuses for the time they have the patient to care for. Once done, 674 
they pass the patient over to the next care giver. The complexity of the organization is such 675 
that no one has any overview or full control of the entire care pathway. This was a primary 676 
need that was addressed by the ERAS group by instituting audit for each and every patient.  677 
Since the patient is treated by many different professionals and they work in different parts 678 
of the hospital, it was necessary to form teams that covered all stations and all professions. 679 
This was the birth of the ERAS Team. This team is led by doctors from surgery and anesthesia 680 
who take the medical responsibility for the care that is delivered and administrated and run 681 
by nurses led by an ERAS coordinating nurse.  682 
A major breakthrough for ERAS came in 2010 when it was reported in meta-analysis 683 
that ERAS reduced complications [143]. Now the data suggested 50% reductions in 684 
complications in colorectal surgery. This sparked a lot of interest and soon ERAS principles 685 
were employed for most major operations in randomized trials and care series, all showing 686 
similar outcomes with faster and better recovery [144]. This also held true for the most 687 
vulnerable patient groups such as the frail and older adults [145]. ERAS also reduces the 688 
impact of risk factors including diabetes [146], undernutrition [147] and facilitates optimal 689 
metabolic and nutritional care [148]. 690 
When ERAS is combined with minimally invasive surgery poor compliance to the 691 
protocol may overshadow the risks associated with co-morbidities [149]. The main 692 
mechanisms behind these improvements are likely to be associated with the marked 693 
reduction in stress reactions to the surgery, since many of the elements of ERAS have this 694 
effect [150]. In colorectal surgery, better compliance with the protocol results in shorter 695 
stay, fewer readmissions, fewer complications [151, 152] and is associated with improved 5-696 
year survival [153].  697 
The variation in care delivery and outcomes is huge worldwide [154], within 698 
continents (76), in countries [155] and between different practitioners [156, 157]. Much of 699 
this variation is due to the slow adoption of modern care and the practice of old and 700 
outdated care principles. The reasons for this are many, but it is interesting to find that the 701 
implementation program run by the ERAS Society has proven to work in all major continents 702 
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and in different socio-economic environments. With the marked reduction in complications 703 
and the opening up of resources with faster recovery and shorter stay the economics of 704 
ERAS is positive regardless of financing of the health care system [158]. 705 
In summary, the evidence-based multi-modal and multi-professional approach to 706 
perioperative care – ERAS – has been shown to markedly improve surgical outcomes and 707 
save cost for care.  708 
 709 
13. Recovery in the community 710 
Following a successful perioperative hospital stay, setting of expectations and thorough 711 
preparation are key to a successful discharge from hospital including pain management, 712 
nutrition, the use of laxatives for return of bowel function, appropriate exercises to help 713 
regain normal function, and having a contact point for any questions. Information should 714 
also be provided surrounding symptoms to be wary of which may indicate the presence of a 715 
complication and what to expect in terms of follow-up. There is good evidence that nursing 716 
telephone follow-up following discharge is positive in terms of providing support and 717 
reassurance for patients [159], as well as reducing hospital readmission rates and improving 718 
patient satisfaction. The process of expectation setting commences with preoperative 719 
counselling [160] where the patient is provided information regarding what to expect on a 720 
daily basis after surgery, identifying the resources available to the patient to facilitate 721 
smooth recovery, and what the patient can do to optimize their outcome. This information 722 
giving is frequently backed up with comprehensive guides and booklets to help them better 723 
understand ERAS programs. In terms of post-discharge from hospital, support from the 724 
district nurse or home helper is invaluable in providing information regarding adequate 725 
nutrition, continued rehabilitation and exercise.  726 
 727 
14. Postoperative nutrition 728 
The instigation of postoperative nutrition should be a part of routine care rather than an 729 
afterthought. In addition, ensuring establishment of early oral nutrition is a fundamental 730 
tenet of ERAS [1].  731 
The mode of nutritional delivery in the early postoperative period has been a subject 732 
of much debate, especially in procedures involving the formation of bowel anastomosis. 733 
However, several studies and systematic reviews with meta-analysis have concluded that 734 
oral and/or enteral is the preferred mode of nutrition for surgical patients. A review of five 735 
feeding routes following pancreaticoduodenectomy showed that nutritional delivery via the 736 
oral route was associated with the least complications [161]. A more recent meta-analysis 737 
using only randomized controlled trials showed enteral to be superior to parenteral nutrition 738 
following pancreaticoduodenectomy [162]. 739 
Avoidance of oral intake, which was felt to reduce the risk of complications, 740 
especially after gastrointestinal surgery involving anastomosis has not been demonstrated in 741 
the setting of any randomized controlled trials. However, this avoidance of nutritional intake 742 
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carries the very real risk of postoperative underfeeding of an already at risk patient group. 743 
This could further exacerbate malnutrition and influence postoperative complication rates.  744 
 There is a distinct requirement of the understanding of this metabolic response and 745 
how to optimize or support the postoperative patient with the appropriate nutritional 746 
therapy especially in instances when the patient is malnourished. The long term caloric and 747 
protein deficits in the post-surgical patient results in poorer postoperative outcomes. 748 
14.1 Early postoperative nutrition 749 
Early nutrition has been shown in abdominal and pelvis surgery to stimulate peristalsis and 750 
GI excretion, reduces the risk of postoperative ileus and shortens overall hospitalization 751 
period. It was observed that patients who had earlier enteral feeding had fewer 752 
complications after colorectal surgery (4.5%) vs 19.4% late enteral nutrition [163]. A 753 
Cochrane review on early enteral nutrition also showed no difference in risk of postoperative 754 
complications in patients fed early (within 24 hours) and those fed late. Importantly they 755 
showed that patients who were fed early had a reduction in mortality RR (0.41, 95% CI 0.18 756 
to 0.93) [164]. An updated review on the same premise found reduction in length of hospital 757 
stay but was inconclusive on postoperative outcomes and quality of life [165]. 758 
14.2 Routes of feeding 759 
The current ESPEN guidelines state that ‘Oral nutritional intake shall be continued after 760 
surgery without interruption and oral intake, including clear liquids, shall be initiated within 761 
hours after surgery in most patients’ [1]. Perioperative nutritional support therapy is 762 
indicated in patients with malnutrition and those at nutritional risk. Perioperative nutritional 763 
therapy should also be initiated, if it is anticipated that the patient will be unable to eat for 764 
more than five days perioperatively. It is also indicated in patients expected to have low oral 765 
intake and who cannot maintain above 50% of recommended intake for more than seven 766 
days. In these situations, it is recommended to initiate nutritional support therapy without 767 
delay. 768 
This is further supported by the systematic reviews and meta-analysis on several 769 
gastrointestinal surgical procedures that have shown no increased benefit of food avoidance 770 
and indeed better outcomes in the patients that received oral nutrition  and those that were 771 
enterally fed [161, 164-166]. In all of these instances they found that early enteral and oral 772 
nutrition was not associated with an increase in clinically relevant complications, but rather 773 
a shorter length of hospital stay [161, 162, 165, 166]. Only in cases If the energy and nutrient 774 
requirements cannot be met by oral and enteral intake alone (<50% of caloric requirement) 775 
for more than seven days, a combination of enteral and parenteral nutrition is 776 





15 Postoperative exercise intervention 781 
Exercise stimulates muscle capillarization, protein synthesis, insulin sensitivity and 782 
mitochondrial function and proliferation, and therefore is a good strategy to maximize 783 
postoperative recovery. However, robust voluntary exercise intervention postoperatively at 784 
a time when metabolic dysregulation and fatigue are at their greatest is unlikely to be 785 
practicable, and fatigue may persist for many weeks after surgery [167]. Furthermore, 786 
muscle wasting and deconditioning will be exacerbated by prolonged periods of bed-rest 787 
[44]. In this situation, non-voluntary, transcutaneous, electrically evoked muscle contraction 788 
may be an effective strategy for the maintaining or improving muscle mass and function 789 
after surgery until voluntary exercise, which is likely to be most effective, is practicable 790 
[168]. Given muscle mass restoration following wasting is known to be slower and of less 791 
magnitude in older people [169], resistance exercise intervention in older people will need 792 
to be supervised and intensive to be successful. Patient muscle mass restoration may be 793 
augmented if exercise intervention is combined with protein nutrition, although this is 794 
controversial providing the volunteer is in protein balance[170]. 795 
 796 
16. The role of novel nutrients and substrates 797 
In the last decades, standard enteral and parenteral formulas have been supplemented with 798 
specific nutrients and substrates with the goal of improving several metabolic pathways, 799 
which are deranged by surgical injury. The peculiar and unique mechanisms of action of 800 
some substrates, established first in experimental settings, encouraged the induction of 801 
clinical trials. 802 
 803 
16.1 Glutamine 804 
Glutamine is involved in a variety of biological processes, such as anabolic functions, acid-805 
base regulation in the kidney, and ammonia metabolism [171]. Depletion in glutamine 806 
storage during stressful events [172] has been reported, and an exogenous supplementation 807 
is associated with improved protein synthesis, preservation of gut barrier, enhancement of 808 
wound healing, reduction of oxidative stress, negative nitrogen balance, improvement of 809 
glucose metabolism, and modulation of the immune system [173].  810 
Until 2007, several randomized, but underpowered, clinical trials (RCTs) have been 811 
published and when the results were pooled in  a meta-analysis [174], the effect of 812 
parenteral or enteral glutamine supplementation resulted in a significant reduction of 813 
surgical morbidity and duration of hospitalization. In 2009, the largest RCT (n=428) on the 814 
impact of the parenteral glutamine supplementation (0.4 g/kg/day) in major abdominal 815 
operations for cancer, rejected the hypothesis of a protective effect on any type of surgery-816 
related morbidity and on the length of hospital stay [175]. More recently a multicenter 817 
double-blind RCT was reported including 150 surgical ICU patients without renal or hepatic 818 
failure, or shock. All received isonitrogenous isocaloric parenteral nutrition (1.5 g/kg/day). In 819 
the intervention group, glutamine was administered in the standard dosage of 0.5 g/kg/day. 820 
No significant differences were seen with the primary endpoints of hospital mortality and 821 
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infection rate (mortality glutamine vs. standard 14.7% vs. 17.3%, bloodstream infection rate 822 
9.6 vs. 8.4 per 1000 hospital days) [176].  823 
A recent meta-analysis [177], included 19 RCTs with 1243 patients scheduled for 824 
elective major abdominal surgery. Glutamine supplementation did not affect overall 825 
morbidity (RR = 0.84; p = 0.473) and infectious morbidity (RR = 0.64; p = 0.087). Patients 826 
treated with glutamine had a significant reduction in length of hospital stay.  827 
 828 
16.2 Omega-3 fatty acids 829 
Fatty acids are potent modulators of the immune and inflammatory responses. They are 830 
incorporated into the cell membrane influencing the function and structure. By penetrating 831 
into the cell cytoplasm, fatty acids affect the synthesis of eicosanoids, cytokines and several 832 
other key mediators. Furthermore, they impact on gene expression and cell signaling. In 833 
addition, the cell-mediated immune responses are deeply affected by different type of fatty 834 
acids. Specifically, omega-3 fatty, as opposite to omega-6 acids, stimulate the synthesis of 835 
less proinflammatory leukotrienes, prostaglandins, and thromboxanes [178]. 836 
Despite the strong molecular background, robust clinical studies on the effect of 837 
parenteral formulas containing omega-3 fatty acid-based lipid emulsion are limited. The 838 
largest RCT on this topic showed no significant difference between treatment and control 839 
arms in postoperative complication rates with an associated and unexplained 5-day 840 
reduction in LOS in the group receiving omega-3 fatty acids [179]. A recent systematic review 841 
and meta-analysis collected 49 RCTs addressing the impact of omega-3 fatty acids on surgical 842 
outcomes [180], but only 24 studies, with a total of 2154 patients, reported the rate of 843 
postoperative infections. Regardless of the commercial formulation used, the risk ratio was 844 
in favor of the group receiving omega-3 fatty acids (RR=0.60; 95%CI [0.490, 0.72]). As 845 
properly emphasized by the authors, the major constraint of this meta-analysis [180], as well 846 
as others [181], was the inclusion of underpowered and non-significant trials. This limitation 847 
could have produced overstating results.  848 
 849 
16.3 Enteral feeds containing multiple substrates 850 
Most of the evidence suggesting that specific nutrients may modulate the clinical course of 851 
patients undergoing major operations has been produced by testing, enteral or oral formulas 852 
enriched with arginine, omega-3 fatty acids and ribonucleotides [182, 183].  853 
The evidence has been extensively argued and reported in the 2017 ESPEN guideline 854 
on clinical nutrition in surgery [1]. The author recommendations were as follows: “peri- or at 855 
least postoperative administration of specific formulae enriched with immunonutrients 856 
should be given in malnourished patients undergoing major cancer surgery. There is 857 
currently no clear evidence for the use of these formulae enriched with immunonutrients 858 
versus standard oral nutritional supplements exclusively in the preoperative period”. These 859 
statements were based after the authors’ systematic search for studies and reviews 860 
published between 2010 and 2015. However, a recent focused meta-analysis on 861 
preoperative immune modulating nutrition in gastrointestinal cancer only, has 862 
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demonstrated a significant reduction in infectious complications and tendency to a shorter 863 
length of stay [182].  864 
It should be highlighted that the vast majority of the published RCTs on 865 
immunonutrition in surgical patients were conducted outside the implementation of ERAS 866 
protocols. The beneficial effect of the administration of immunonutrients, in addition to 867 
ERAS pathways has been addressed in recent multicenter Spanish RCT [184]. They studied 868 
this association in well-nourished patients undergoing colorectal resection for cancer. The 869 
findings demonstrated a decrease in the total number of complications observed in the 870 
immunonutrition treated group compared with the control group, primarily due to a 871 
reduction in infectious complications (23.8% vs.10.7%, P=0.0007). These findings look 872 
promising but necessitate future confirmations.  873 
 874 
17. Pre-, pro- and syn-biotics in the surgical patient 875 
Probiotics, as defined by the World Health Organisation are live microorganisms which, 876 
when administered in adequate amounts, confer a health benefit on the host. They survive 877 
transit through the gastrointestinal tract with the majority of their activity being in the colon 878 
[185]. Prebiotics are carbohydrate compounds, primarily oligosaccharides which induce 879 
growth and/or activity of selective bacterial genera in the colon [186]. Combinations of 880 
prebiotics and probiotics in a single preparation are referred to as synbiotics [185]. Current 881 
literature suggests that multispecies preparations are more effective due to better survival 882 
of the gastro-duodenal passage or greater ability to find a biological niche. However, to date, 883 
the most appropriate species of probiotic has not been described in the currently available 884 
literature.  885 
Probiotics have been used in the treatment of several abdominal complaints. They 886 
have been shown to be useful in the treatment of gastrointestinal infections, for oral 887 
rehydration therapy in treating acute infectious diarrhea in children [187-190], traveller’s 888 
diarrhea [191] and antibiotic-associated diarrhea in both children [192-194] and adults [195-889 
198]. Recent ESPEN guidelines stated that use of a specific probiotic multi strain mixture may 890 
be beneficial for primary and secondary prevention of pouchitis in patients with UC who 891 
have undergone colectomy and ileo- anal pouch anastomosis. There are some data to 892 
confirm the use of the same multi strain probiotic mixture for the treatment of pouchitis 893 
after antibiotic treatment failure as well as for the treatment of mild to moderate ulcerative 894 
colitis [199]. The suggested mechanisms of action include both a direct antimicrobial effects 895 
as well as indirectly or competitively excluding potentially pathogenic bacteria [200]. They 896 
achieve this by producing bacteriocins which inhibit pathogenic epithelial adherence and 897 
production of virulence factor, and prevent bacterial translocation via tight junctions [200, 898 
201]. They also alter gut microenvironment by altering the mucosal pH, which further 899 
inhibits pathogenic bacteria. Additionally, others have shown that probiotic bacteria can 900 
hamper the inflammatory response by promoting anti-inflammatory cytokine production 901 
[200, 202]. Whilst these nutritional adjuncts are emerging as potential treatments that could 902 
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help reduce the incidence of postoperative infection, the success or failure of one strain 903 
cannot be extrapolated to other strains.  904 
To the post-surgical patient, the stress of the operative procedure can lead to a 905 
proinflammatory stimulus that increases gut permeability. Increased gut permeability 906 
together with dysbiosis may lead to increased bacterial translocation across the gut barrier 907 
into the circulation. Bacterial translocation is an important pathogenic factor for the 908 
increased risk of infections. To this end the introduction of probiotics or synbiotics would be 909 
expected to maintain gut barrier function by restoring intestinal permeability ameliorating 910 
the intestinal inflammatory response and the release of cytokines, and maintaining the 911 
homeostasis of the normal gut microbiota.  912 
A number of randomized controlled trials (RCTs) have examined the value of 913 
prebiotics and probiotics in reducing postoperative complications in particular post-914 
operative infective complications. The interest in synbiotics, is based on emerging evidence 915 
that the proliferation of probiotic bacteria can be enhanced by the co-administration of 916 
prebiotics [203]. Indeed a more recent meta-analysis has shown that whilst infectious 917 
complications were reduced after elective abdominal surgery, the effect was better still in 918 
those patients who received synbiotics [204]. 919 
Contrastingly, some studies have yielded mixed results that probably are due to the 920 
variations of probiotics used, methodological quality and study endpoints. Additionally, 921 
others have described adverse events surrounding probiotics use. It is, however, noteworthy 922 
that serious adverse effects of probiotics are uncommon in those who are well. In patients 923 
with severe pancreatitis, administration of probiotics was associated with an increased 924 
frequency of bowel ischemia – the mechanism of this is still unexplained [205-207]. 925 
However, this effect of probiotics has not been identified in any other study.  In the most 926 
recent meta-analysis [204], no serious adverse events were noted. They concluded that 927 
probiotics and synbiotics are safe in elective gastrointestinal surgery and is associated with a 928 
significant reduction in infectious complications.  929 
 930 
18. Patient and caregiver partnership 931 
The period surrounding a major surgical procedure is highly taxing on patients and their 932 
caregivers. Perioperative nutrition is recognized as a substantial issue, with significant 933 
weight loss not uncommon. Malnutrition in this setting is multifactorial, including issues with 934 
poor appetite, unappealing hospital nutrition, postoperative pain and a reduced level of 935 
consciousness. Support from family is frequently key to optimizing perioperative nutritional 936 
intake and modification of previous eating habits including consuming high calorie foods on 937 
a little but often basis. Oral nutritional supplementation is often met with variable patient 938 
acceptability and hence compliance is often not optimal. The effects of major surgery and 939 
indeed the complications, have wide reaching effects on not just the patient but also their 940 
families and caregivers, rendering them a bystander in the care of their loved ones. The 941 
importance of communication cannot be overemphasized in this setting, and a strong 942 
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partnership between the surgeon and patient, family and caregivers is needed to overcome 943 
complicated postoperative courses. 944 
 945 
19. Future directions for research and policy 946 
The evidence contains many strengths, and these are reflected in high-quality guidelines 947 
surrounding perioperative nutrition [1]. However, there are still many areas of nutrition in 948 
this setting which have not yet been fully explored. An area of research development 949 
surrounds the global obesity epidemic and its link to metabolic syndrome, with more 950 
attention being directed towards a multidisciplinary approach to the management of obesity 951 
and its related diseases [208], tying together concepts such as bariatric and orthopedic 952 
surgery, geriatrics, endocrinology, psychology and psychiatry, as well as nephrology and 953 
dialysis. An area of research which is going to become increasingly relevant is the shift in 954 
population related to the ageing epidemic which is currently underway. With increasing 955 
frailty comes weight loss, progressive skeletal muscle weakness, exhaustion and inactivity, 956 
all of which increase the prevalence of disability, loss of independence and worsened clinical 957 
outcomes.  958 
Not only are there challenges in developing an evidence base for interventions, but 959 
also in the implementation of this evidence once established. One area in which 960 
implementation lags behind the evidence base for its practice is ERAS protocols in surgery, 961 
with a multicenter qualitative study finding the main barriers to implementation being time 962 
restraints, a reluctance to change and the logistics of setup [209]. Another topic is that of 963 
fasting guidelines in enterally fed in critical care patients. Again, this identified issues 964 
surrounding mistrust of the guideline, resistance to a change in clinical practice, as well as 965 
perceived increased clinical complexity which all acted as barriers to implementation. There 966 
are some key concepts which are necessary for increasing implementation which include 967 
promotion of education including resources such as the ESPEN journal, ESPEN consensus 968 
papers, the LLL courses and live-expert courses, as well as improved communication 969 
between members of the multidisciplinary team. This may be facilitated by the creation of 970 
specialty-specific guidelines including a simplified version for community-based care as well 971 
as a patient-orientated version.  972 
 973 
20. Conclusions 974 
These proceedings of the ESPEN Symposium on perioperative care encompass the scientific 975 
basis of nutritional and metabolic care in the perioperative period and also suggest areas for 976 
suture research and change in policy. The main take-home messages are summarized in 977 
Table 4.  978 
 979 
  980 
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Legends for Figures: 1561 
 1562 
Figure 1: Prevalence of decreased eating and association with 30-day hospital mortality in 1563 
preoperative, postoperative and non-surgical patients. Each dot represents 1% prevalence 1564 
within the patient group. Normal eating is shown in green and is the reference category for 1565 
calculation of the univariate odds ratio for death in hospital within 30 days shown as 1566 
estimate with 95% confidence intervals. 1567 
 1568 
Figure 2: Suggested algorithm for perioperative fluid therapy 1569 
 1570 
Figure 3: Elements of Enhanced Recovery After Surgery Pathways in the pre-, intra- and post-1571 
operative periods. 1572 
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Table 1: Definitions of Sarcopenia (taken from the Society on Sarcopenia, Cachexia, and 
Wasting Disorders (SCWD) website).  
Definition Function Muscle Mass 
Sarcopenia and Frailty 
Research Specialist Interest 
Group (SIG) – cachexia-
anorexia in chronic wasting 
disease [25] 
Gait speed <0.8 m/s, OR 
other physical performance 
test 
Low muscle mass (2SD) 
European Working Group of 
Sarcopenia in Older Persons 
(EWGSOP) [21] 
Gait speed <0.8 m/s; grip 
strength 40 kg males, 30 kg 
female 
Low muscle mass (not 
defined) 
IWGS Sarcopenia Task Force 
[22] 
Gait speed <1.0 m/s, grip 
strength 
Low appendicular lean mass 
(<7.23 kg/m
2
 in men, 5.67 
kg/m
2
 in women) 
Sarcopenia with limited 
mobility (SCWD) [10] 
6-minute walk <400 m, OR 
gait speed <1.0 m/s 




Asian Working Group for 
Sarcopenia [23]  
Gait speed <0.8 m/s; grip 
strength 26 kg males, 18 kg 
females 




Foundation for the National 
Institutes of Health [24] 
Gait speed <0.8 m/s; grip 






Table 2: Pathophysiological changes of the systemic inflammatory response 
Neuroendocrine changes 
 Fever, somnolence, fatigue and anorexia 
 Increased adrenal secretion of cortisol, adrenaline and glucagon 
Hematopoietic changes 




 Loss of muscle and negative nitrogen balance 
 Increased Lipolysis 
 Trace metal sequestration 
 Diuresis 
Hepatic changes 
 Increased blood flow 
 Increased acute phase protein production 
 
 
Table 3: Systemic inflammation and its effects on the surgical patient 
Protein catabolism after surgery leads to depletion of lean mass. 
The magnitude of the post-operative systemic inflammatory response corresponds 
to the amount of surgical trauma. 
The higher the response is associated with poorer surgical outcome.   
C-reactive protein is useful in quantifying the magnitude of the post-operative 
systemic response. 
Moderating the post-operative systemic inflammatory response (example by using a 
laparoscopic approach) - appears to improve surgical outcome.   
 
 
Table 4: Take home messages 
 
• History is continuity – those who don’t learn from the lessons of history are 
condemned to repeat it. 
• Preoperative muscle mass is critical to postoperative outcome. 
• Sarcopenic obesity is an independent predictor of postoperative complications, 
especially when the host genotype is associated with weight loss and a low skeletal 
muscle index. 
• Surgical patients who don’t eat when eating is allowed and an increased length of 
stay when compared with those who are not allowed to eat. 
• Nutritional risk score (NRS) is validated for surgical patients and should be 
performed at least 10 days before surgery. 
• The perioperative period should be used for conditioning regimens like 
prehabilitation. 
• High blood glucose concentrations in patients who were normoglycemic previously 
are associated with increased postoperative complications. 
• Excess 0.9% saline is detrimental in the perioperative period and salt and water 
overload of >2.5 L is associated with adverse outcome. 
• Enhanced Recovery After Surgery principles are appropriate for all patients, but 
good results are dependent on a challenging inter-disciplinary cooperation to 
ensure high compliance rates. 
• Inflammation is a marker for surgical complications and CRP profiling is useful. 
• The effects of nutrients are dissociated from nutrition and there is a role for 
pharmaconutrition. 
• Dysbiosis contributes to inflammation – the effects of pre-, pro- and synbiotics 
depends on species, strains and adjuncts. 
• Postoperative fatigue inhibits voluntary exercise, immobilization induces anabolic 
resistance, and the lower the anabolic response to feeding, the higher the muscle 
loss. 
• Perioperative nursing in the hospital and community after discharge is a key 
component for good outcome. 
• A strong partnership between the surgeon and patient/family/caregivers is needed 
to overcome complicated postoperative courses. 
 



